Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide.
Arena Pharmaceuticals Competitors
Price History & Performance
|Historical stock prices|
|Current Share Price||US$59.69|
|52 Week High||US$45.50|
|52 Week Low||US$90.19|
|1 Month Change||13.85%|
|3 Month Change||-12.48%|
|1 Year Change||-21.05%|
|3 Year Change||30.64%|
|5 Year Change||224.40%|
|Change since IPO||-76.12%|
Recent News & Updates
|ARNA||US Biotechs||US Market|
Return vs Industry: ARNA underperformed the US Biotechs industry which returned 23.8% over the past year.
Return vs Market: ARNA underperformed the US Market which returned 32.8% over the past year.
Stable Share Price: ARNA is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ARNA's weekly volatility (7%) has been stable over the past year.
About the Company
Arena Pharmaceuticals, Inc., a biopharmaceutical company, focuses on providing novel medicines with pharmacology and pharmacokinetics to patients worldwide. Its investigational clinical programs include Etrasimod (APD334) that is in Phase III clinical trial for ulcerative colitis, Phase IIb/III clinical trial for Crohn’s disease, Phase II clinical trial for alopecia areata, Phase III clinical trial for atopic dermatitis, and Phase IIb clinical trial for eosinophilic esophagitis; Olorinab (APD371), which is in Phase IIb clinical trial for the treatment of abdominal pain associated with irritable bowel syndrome; APD418 that is in Phase I clinical trial for acute heart failure; and Temanogrel for coronary microvascular obstruction is in Phase II clinical trial. It also develops ralinepag (APD811), which is in Phase III clinical trial for pulmonary arterial hypertension.
Arena Pharmaceuticals Fundamentals Summary
|ARNA fundamental statistics|
Is ARNA overvalued?See Fair Value and valuation analysis
Earnings & Revenue
|ARNA income statement (TTM)|
|Cost of Revenue||US$395.25m|
Last Reported Earnings
Jun 30, 2021
Next Earnings Date
|Earnings per share (EPS)||-7.93|
|Net Profit Margin||-849,317.54%|
How did ARNA perform over the long term?See historical performance and comparison
Is Arena Pharmaceuticals undervalued compared to its fair value and its price relative to the market?
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: Insufficient data to calculate ARNA's fair value to establish if it is undervalued.
Significantly Below Fair Value: Insufficient data to calculate ARNA's fair value to establish if it is undervalued.
Price To Earnings Ratio
PE vs Industry: ARNA is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ARNA is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ARNA's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ARNA is overvalued based on its PB Ratio (3.8x) compared to the US Biotechs industry average (3.3x).
How is Arena Pharmaceuticals forecast to perform in the next 1 to 3 years based on estimates from 15 analysts?
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ARNA is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ARNA is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ARNA is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ARNA's revenue (76% per year) is forecast to grow faster than the US market (9.8% per year).
High Growth Revenue: ARNA's revenue (76% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ARNA is forecast to be unprofitable in 3 years.
How has Arena Pharmaceuticals performed over the past 5 years?
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ARNA is currently unprofitable.
Growing Profit Margin: ARNA is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ARNA is unprofitable, and losses have increased over the past 5 years at a rate of 20.5% per year.
Accelerating Growth: Unable to compare ARNA's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ARNA is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (4.9%).
Return on Equity
High ROE: ARNA has a negative Return on Equity (-49.85%), as it is currently unprofitable.
How is Arena Pharmaceuticals's financial position?
Financial Position Analysis
Short Term Liabilities: ARNA's short term assets ($990.4M) exceed its short term liabilities ($64.8M).
Long Term Liabilities: ARNA's short term assets ($990.4M) exceed its long term liabilities ($48.7M).
Debt to Equity History and Analysis
Debt Level: ARNA is debt free.
Reducing Debt: ARNA has not had any debt for past 5 years.
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ARNA has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: ARNA has sufficient cash runway for 2 years if free cash flow continues to reduce at historical rates of 3.5% each year.
What is Arena Pharmaceuticals's current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ARNA's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ARNA's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ARNA's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ARNA's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ARNA's dividend in 3 years as they are not forecast to pay a notable one for the US market.
How experienced are the management team and are they aligned to shareholders interests?
Average management tenure
Amit Munshi (53 yo)
Mr. Amit D. Munshi, MBA, serves as the Chairman of the Board at Galecto, Inc. since May 2020. Mr. Munshi has been the Chief Executive Officer and President of Arena Pharmaceuticals, Inc. since May 11, 2016...
CEO Compensation Analysis
Compensation vs Market: Amit's total compensation ($USD6.90M) is above average for companies of similar size in the US market ($USD5.22M).
Compensation vs Earnings: Amit's compensation has been consistent with company performance over the past year.
Experienced Management: ARNA's management team is considered experienced (3.1 years average tenure).
Experienced Board: ARNA's board of directors are considered experienced (3.7 years average tenure).
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: ARNA insiders have bought more shares than they have sold in the past 3 months.
Recent Insider Transactions
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 5.9%.
Arena Pharmaceuticals, Inc.'s employee growth, exchange listings and data sources
- Name: Arena Pharmaceuticals, Inc.
- Ticker: ARNA
- Exchange: NasdaqGS
- Founded: 1997
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$3.646b
- Shares outstanding: 61.07m
- Website: https://www.arenapharm.com
Number of Employees
- Arena Pharmaceuticals, Inc.
- 136 Heber Avenue
- Park City
- United States
Company Analysis and Financial Data Status
|Data||Last Updated (UTC time)|
|Company Analysis||2021/09/28 23:13|
|End of Day Share Price||2021/09/28 00:00|
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.